Pierre Fab­ry forges I/O dis­cov­ery pact; Ac­tini­um surges on CHMP sup­port

→ France’s Pierre Fab­re struck a deal with H-Im­mune SAS to de­vel­op new im­munother­a­pies, uti­liz­ing H-Im­mune’s tech­nol­o­gy plat­form to gen­er­ate lead can­di­dates of ful­ly hu­man an­ti­bod­ies to serve as the ini­tial step in a pro­gram to de­vel­op im­muno-on­col­o­gy ther­a­peu­tics. “This trans­ac­tion strength­ens Pierre Fab­re’s po­si­tion in the ar­eas of im­muno-on­col­o­gy and nov­el cut­ting-edge bio­ther­a­peu­tics,” said Lau­rent Au­doly, head of R&D of Pierre Fab­re Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.